KYTX vs NTAP · $488.8M cap vs P/E 28, rev $6.24B
Kyverna Therapeutics, Inc. Common Stock (KYTX) versus NetApp Inc (NTAP) — a side-by-side from cached financials, not a winner call.
Kyverna Therapeutics, Inc. Common Stock (KYTX) is a biotechnology company listed on NASDAQ.
NetApp Inc (NTAP) is a software - infrastructure company listed on US.
KYTX does not have a complete income-statement cache yet.
Latest reported NTAP revenue for 2026-04-24 was $6.24B. Net income was $1.28B. Revenue was down 5.1% from 2025-04-25 to 2026-04-24. NTAP currently screens at market cap $35.43B and trailing P/E 28.2.
KYTX currently screens at market cap $488.8M. NTAP currently screens at market cap $35.43B and trailing P/E 28.2.
Not investment advice. Open the KYTX and NTAP stock pages for the full models.
Not investment advice.